

Diaceutics PLC
("Diaceutics" or the "Company")

Sale of Shares and PDMR Shareholding

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that on 12 May 2021, Jordan Clark, the Chief Commercial Officer of Diaceutics, sold 50,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 124.5 pence per Ordinary Share. As a result of the sale, Jordan's shareholding is 855,190 Ordinary Shares, representing approximately 1.02% of the Company's issued share capital.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Alma PR

Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny
Michael Johnson (Sales)

+44 (0)207 397 8900

Alma PR

Caroline Forde
Robyn Fisher
Kieran Breheny

Tel: +44 (0)20 3405 0205 or diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com

About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Jordan Clark
2 Reason for notification		
a.	Position/Status	Chief Commercial Officer
b.	Initial notification/	Initial

	Amendment					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Sale of Ordinary Shares				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>124.5 p</td> <td>50,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	124.5 p	50,000
Price(s)	Volume(s)					
124.5 p	50,000					
e.	Date of the transaction	12 May 2021				
f.	Place of the transaction	AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHATMFTMTABBFB